Boston Scientific (BSX) Ticks Higher Following FDA Approval of Stent System
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Nasdaq falls ahead of earnings, economic data while oil rallies
- Oil prices rise on Saudi Arabia attacks, overshadowing Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
Tweet
Share
E-mailGet Alerts BSX Hot Sheet
Join SI Premium – FREE
Boston Scientific Corp. (NYSE: BSX) shares are up in after-hours trading following reports it received U.S. FDA approval for its Epic Vascular Self-Expanding Stent System. Shares are about 4.6 percent higher.
For more color on the approval, click here.
For more color on the approval, click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- U.S. MedTech stocks: Q3 earnings preview
- Stoke Therapeutics shares STK-002 data for eye disorder at AAO
- Odyssey Therapeutics to present OD-001 combo trial design at ACG 2026
Create E-mail Alert Related Categories
FDA, Insiders' BlogSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
